Stromedix gains license to fibrosis tech
Stromedix Inc. has acquired exclusive rights to a compound, called αvβ5, developed at the University of California San Francisco (UCSF). The compound has been identified as playing a role in acute and chronic organ failure.
The Cambridge biotech focuses on creating therapies for fibrosis and fibrotic organ failure. Fibrosis is caused by the body’s attempt to repair chronic tissue injury. Over a period of years, this process can leave scar tissue in affected organs and disrupt normal tissue functions and even cause organ failure.